Literature DB >> 8609720

Functional inactivation of wild-type p53 protein correlates with loss of IL-2 dependence in HTLV-I transformed human T lymphocytes.

R B Gartenhaus1, P Wang.   

Abstract

Human T cell leukemia virus type-I (HTLV-I), the etiologic agent of adult T cell leukemia (ATL) transforms human T cells in vitro and in vivo. Tax, the major transactivator of HTLV-I is critical for the initial events involved in transformation, however, the later steps required for progression from an IL-2 dependent state to one of IL-2 independence remain to be clarified. We investigated the potential role of p53 protein in this process employing several IL-2 dependent and independent HTLV-I transformed cell lines. All cell lines examined were found to be wild-type in the p53 coding region usually associated with inactivating mutations using RT-PCR-SSCP analysis and DNA sequencing. Levels of p53 protein were consistently higher in IL-2 independent lines compared to IL-2 dependent ones. Lack of functional p53 activity was observed only in IL-2 independent cell lines using a transfection assay with a B-galactosidase reporter gene construct responsive to wild-type p53 protein. Increased steady state levels of wild-type p53 protein associated with its functional inactivation appear to be linked to the loss of IL-2 dependent growth in HTLV-I transformed lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8609720

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  10 in total

Review 1.  Insight into the tumor suppressor function of CBP through the viral oncoprotein tax.

Authors:  K Van Orden; J K Nyborg
Journal:  Gene Expr       Date:  2000

Review 2.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

3.  p53 recruitment of CREB binding protein mediated through phosphorylated CREB: a novel pathway of tumor suppressor regulation.

Authors:  H A Giebler; I Lemasson; J K Nyborg
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

4.  Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein.

Authors:  C A Pise-Masison; K S Choi; M Radonovich; J Dittmer; S J Kim; J N Brady
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

5.  Differences in the ability of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 tax to inhibit p53 function.

Authors:  R Mahieux; C A Pise-Masison; P F Lambert; C Nicot; L De Marchis; A Gessain; P Green; W Hall; J N Brady
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells.

Authors:  C A Pise-Masison; M Radonovich; K Sakaguchi; E Appella; J N Brady
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

7.  Human T-cell lymphotropic/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB/ATF functional domain.

Authors:  J C Mulloy; T Kislyakova; A Cereseto; L Casareto; A LoMonico; J Fullen; M V Lorenzi; A Cara; C Nicot; C Giam; G Franchini
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

8.  The HTLV-1-encoded protein HBZ directly inhibits the acetyl transferase activity of p300/CBP.

Authors:  Torsten Wurm; Diana G Wright; Nicholas Polakowski; Jean-Michel Mesnard; Isabelle Lemasson
Journal:  Nucleic Acids Res       Date:  2012-03-19       Impact factor: 16.971

9.  Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia.

Authors:  Wei Ju; Meili Zhang; Michael Petrus; Michiyuki Maeda; Cynthia A Pise-Masison; Thomas A Waldmann
Journal:  Retrovirology       Date:  2014-06-02       Impact factor: 4.602

10.  Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells.

Authors:  Xue Tao Bai; Ramona Moles; Hassiba Chaib-Mezrag; Christophe Nicot
Journal:  J Hematol Oncol       Date:  2015-10-23       Impact factor: 17.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.